StockMacro
Company, fund or insider

Help

Menu

aTyr Pharma

$3.82 -80% in 6 monthsMarket cap $9.7M

ATYR on XNAS, Health Care, aTyr Pharma, Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 85% in a year to $3.82 while the $53.3M annual loss runs against $48.8M cash.

  • BadInstitutional holders fell to 71 from 90 last quarter, down 21%
  • WatchShort interest 12% of shares, down 97% on the prior report

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
58
Website
atyrpharma.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 4 Mar 2027 (an estimate: a year ago it reported on 5 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $18.3M.
Quarter to 31 Dec 2021: revenue –, net income -$8.6MQuarter to 31 Mar 2022: revenue –, net income -$12.2MQuarter to 30 Jun 2022: revenue –, net income -$12.4MQuarter to 30 Sep 2022: revenue $0, net income -$13.2MQuarter to 30 Sep 2022: revenue $0, net income -$13.2MQuarter to 31 Dec 2022: revenue $10.4M, net income –Quarter to 31 Mar 2023: revenue $0, net income -$12.0MQuarter to 31 Mar 2023: revenue $0, net income -$12.0MQuarter to 30 Jun 2023: revenue $0, net income -$12.3MQuarter to 30 Jun 2023: revenue $0, net income -$12.3MQuarter to 30 Sep 2023: revenue $353K, net income -$11.3MQuarter to 30 Sep 2023: revenue $353K, net income -$11.3MQuarter to 31 Dec 2023: revenue $0, net income -$14.8MQuarter to 31 Dec 2023: revenue $0, net income -$14.8MQuarter to 31 Mar 2024: revenue $235K, net income -$15.5MQuarter to 31 Mar 2024: revenue $235K, net income -$15.5MQuarter to 30 Jun 2024: revenue $0, net income -$16.3MQuarter to 30 Jun 2024: revenue $0, net income -$16.3MQuarter to 30 Sep 2024: revenue $0, net income -$17.3MQuarter to 30 Sep 2024: revenue $0, net income -$17.3MQuarter to 31 Dec 2024: revenue $0, net income -$15.0MQuarter to 31 Dec 2024: revenue $0, net income -$15.0MQuarter to 31 Mar 2025: revenue $0, net income -$14.9MQuarter to 31 Mar 2025: revenue $0, net income -$14.9MQuarter to 30 Jun 2025: revenue $0, net income -$19.5MQuarter to 30 Jun 2025: revenue $0, net income -$19.5MQuarter to 30 Sep 2025: revenue $190K, net income -$25.7MQuarter to 30 Sep 2025: revenue $190K, net income -$25.7MQuarter to 31 Dec 2025: revenue $0, net income -$14.0MQuarter to 31 Dec 2025: revenue $0, net income -$14.0MQuarter to 31 Mar 2026: revenue –, net income -$10.8MQuarter to 30 Jun 2026: revenue –, net income -$10.3MQuarter to 30 Sep 2026: revenue $0, net income -$18.3MQuarter to 30 Sep 2026: revenue $0, net income -$18.3M
31 Dec 2021RevenueNet incomeNet losstallest bar $25.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$18.3M
30 Jun 2026–-$10.3M
31 Mar 2026–-$10.8M
31 Dec 2025$0-$14.0M
30 Sep 2025$190K-$25.7M
30 Jun 2025$0-$19.5M
31 Mar 2025$0-$14.9M
31 Dec 2024$0-$15.0M
30 Sep 2024$0-$17.3M
30 Jun 2024$0-$16.3M
31 Mar 2024$235K-$15.5M
31 Dec 2023$0-$14.8M
30 Sep 2023$353K-$11.3M
30 Jun 2023$0-$12.3M
31 Mar 2023$0-$12.0M
31 Dec 2022$10.4M–
30 Sep 2022$0-$13.2M
30 Jun 2022–-$12.4M
31 Mar 2022–-$12.2M
31 Dec 2021–-$8.6M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – $190K
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$53.3M -$75.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -93.4% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$43.9M -$63.0M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $48.8M $85.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $13.33
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.29 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
aTyr PharmaATYR (this company) $9.7Mloss–––
Jasper TherapeuticsJSPR $9.6Mloss–––
TScan TherapeuticsTCRX $9.9Mloss1.9-38%–
Dyadic InternationalDYAI $11.5Mloss3.7-7.6%-227%
IN8bioINAB $8.2Mloss–––
Intensity TherapeuticsINTS $8.2Mloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-21%

71 13F filers vs 90

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

27.8M shares held by 13F filers (30 Sep 2026) of 2.5M outstanding (2 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

12%

293K shares sold short (30 Oct 2026) of 2.5M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.4

293K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-97%

10.3M shares sold short in the report before, 293K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

57%

57% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 46%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

11 articles in the last 7 days; its usual week has 1.

Price $3.82 on 20 Nov 2026, -85% over 12 months (12-month range $3.69 to $42.00)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $44K in the last 12 months (the 12 months before: $920K).
Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.
Capital spending per quarter. Capital spending $45K in the latest quarter, +22% on a year earlier.
Institutional holders (13F filers). 71 13F filers reported holding it in the latest 13F quarter, -28% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
31 Jul 20268-K and other filingsA major agreement ended
8 Jun 20268-K and other filingsDelisting notice or listing transfer
5 Dec 20258-K and other filingsDelisting notice or listing transfer
14 Oct 2025Sharp changeShort interest spike: short interest spike, 37.9M vs usual 7.6M (2025-09-30); 27.8x the same period a year earlier
30 Sep 2025Sharp changeShort interest spike: short interest spike, 33.1M vs usual 6.1M (2025-09-15); 48.3x the same period a year earlier
16 Sep 2025Sharp changeShort interest spike: short interest spike, 29.4M vs usual 4.8M (2025-08-29); 66.7x the same period a year earlier
2 Sep 2025Sharp changeShort interest spike: short interest spike, 28.2M vs usual 4.1M (2025-08-15); 81.5x the same period a year earlier
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 47 vs usual 10.50 (2025-06-30); 11.8x the same period a year earlier
12 Aug 2025Sharp changeShort interest spike: short interest spike, 25.6M vs usual 3.7M (2025-07-31); 94.6x the same period a year earlier
7 Aug 20258-K and other filingsAsset write-down (impairment)
29 Jul 2025Sharp changeShort interest spike: short interest spike, 20.4M vs usual 3.6M (2025-07-15); 60.6x the same period a year earlier
6 May 20258-K and other filingsDirector or officer change
6 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Feb 2025Sharp changeMany funds opening a new position: many funds opening a new position, 27 vs usual 8.50 (2024-12-31); 4.5x the same period a year earlier
12 Dec 20248-K and other filingsDirector or officer change
12 Dec 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Jun 2024Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 133K)
29 May 20248-K and other filingsDirector or officer change
29 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 May 20238-K and other filingsDirector or officer change
19 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Apr 20228-K and other filingsDirector or officer change
28 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Apr 20228-K and other filingsA major agreement ended
Insider net buying (open market)
Month from 1 Jan 2022: $47K published
Month from 1 Jul 2022: $43K published
Month from 1 Nov 2022: $21K published
Month from 1 Feb 2023: -$4K published
Month from 1 May 2023: $450K published
Month from 1 Aug 2023: $30K published
Month from 1 Nov 2023: $17K published
Month from 1 Dec 2023: $18K published
Month from 1 Feb 2024: -$3K published
Month from 1 Jun 2024: $142K published
Month from 1 Jul 2024: $184K published
Month from 1 Feb 2025: -$8K published
Month from 1 Mar 2025: $15K published
Month from 1 Oct 2025: $913K published
Month from 1 Feb 2026: -$6K published
Month from 1 May 2026: $50K published
Revenue per quarter
Quarter ended 30 Sep 2022: $0; public on 10 Nov 2023
Quarter ended 31 Dec 2022: $10.4M; public on 15 Mar 2023
Quarter ended 31 Mar 2023: $0; public on 3 May 2024
Quarter ended 30 Jun 2023: $0; public on 14 Aug 2024
Quarter ended 30 Sep 2023: $353K; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $0, -100% on a year earlier; public on 15 Mar 2024
Quarter ended 31 Mar 2024: $235K; public on 3 May 2024
Quarter ended 30 Jun 2024: $0; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $0; public on 14 Mar 2025
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $0; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $190K; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 6 Mar 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 7 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $18K, +260% on a year earlier; public on 16 Mar 2022
Quarter ended 31 Mar 2022: $43K, +153% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $53K, -45% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $426K, +598% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $1.1M, +6117% on a year earlier; public on 15 Mar 2023
Quarter ended 31 Mar 2023: $1.2M, +2798% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $2.4M, +4419% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $557K, +31% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Mar 2024: $17K, -99% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $8K, -100% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $15K, -97% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $25K; public on 14 Mar 2025
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $9K, +12% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $37K, +147% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $31K, +24% on a year earlier; public on 6 Mar 2026
Quarter ended 31 Mar 2026: $138K; public on 16 May 2026
Quarter ended 30 Jun 2026: $73K, +711% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $45K, +22% on a year earlier; public on 7 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 46; public on 14 Feb 2022
31 Mar 2022 report: 39; public on 16 May 2022
30 Jun 2022 report: 34; public on 15 Aug 2022
30 Sep 2022 report: 29; public on 14 Nov 2022
31 Dec 2022 report: 35; public on 14 Feb 2023
31 Mar 2023 report: 34; public on 15 May 2023
30 Jun 2023 report: 39; public on 14 Aug 2023
30 Sep 2023 report: 36; public on 14 Nov 2023
31 Dec 2023 report: 42; public on 14 Feb 2024
31 Mar 2024 report: 55; public on 15 May 2024
30 Jun 2024 report: 42; public on 14 Aug 2024
30 Sep 2024 report: 52; public on 14 Nov 2024
31 Dec 2024 report: 76; public on 14 Feb 2025
31 Mar 2025 report: 86; public on 15 May 2025
30 Jun 2025 report: 105; public on 14 Aug 2025
30 Sep 2025 report: 99; public on 14 Nov 2025
31 Dec 2025 report: 77; public on 17 Feb 2026
31 Mar 2026 report: 106; public on 15 May 2026
30 Jun 2026 report: 90; public on 14 Aug 2026
30 Sep 2026 report: 71; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $50K (28 May 2026), 2.9× its normal reading; higher than 59% of its own history.
  • Insider net buying (open market): Insiders bought a net $44K in the last 12 months (the 12 months before: $920K).
  • Revenue per quarter: Revenue $0 in the latest quarter, -100% on a year earlier.
  • Capital spending per quarter: Capital spending $45K in the latest quarter, +22% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 72 insider trades

No trades in the last 90 days; the latest was filed 28 May 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
28 May 2026Paul SchimmelDirectorBuy100,000$0.50$50KForm 4
4 Feb 2026Sanjay ShuklaPresident and CEOSellafter exercising options3,745$0.98$4KForm 4
4 Feb 2026Jill Marie BroadfootChief Financial OfficerSellafter exercising options1,558$0.98$2KForm 4
4 Feb 2026Nancy DenyesGeneral CounselSellafter exercising options1,118$0.98$1KForm 4
9 Oct 2025Paul SchimmelDirectorBuy1,000,000$0.91$913KForm 4
17 Mar 2025Jane A GrossDirectorBuy3,750$4.00$15KForm 4
4 Feb 2025Jill Marie BroadfootChief Financial OfficerSellafter exercising options1,254$3.78$5KForm 4
4 Feb 2025Nancy DenyesGeneral CounselSellafter exercising options899$3.78$3KForm 4

71 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 10 opened a position, 27 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Federated Hermes, Inc.5.0M194.8%$1.5M-3.5M-42%
Vanguard Capital Management LLC3.8M147.6%$1.1M-46K-1.2%
Gsa Capital Partners LLP3.4M134.2%-34K-1.0%
Kalehua Capital Management LLC1.8M71.8%$554K-1.7M-49%
FMR LLC (Fidelity)1.8M69.9%$540K-690K-28%
BlackRock, Inc.1.6M63.6%$491K-207K-11%
Jacobs Levy Equity Management, Inc1.4M54.1%$418KNew+1.4M
Geode Capital Management, LLC1.2M47.3%$366K+30K+2.5%
UBS Group AG1.2M45.7%$353K-365K-24%
Morgan Stanley1.1M43.2%$334K-243K-18%

Company events

All 49 company events

In 12 months: 2 delisting notices, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
31 Jul 2026A major agreement ended8-K
8 Jun 2026Delisting notice or listing transfer8-K
5 Dec 2025Delisting notice or listing transfer8-K
7 Aug 2025Asset write-down (impairment)8-K
6 May 2025Director or officer changeSame filing: shareholder vote results8-K
23 Dec 2024Signed a major agreement8-K
12 Dec 2024Director or officer change8-K
29 May 2024Director or officer changeSame filing: shareholder vote results8-K

The 5 newest of 97 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

14 Aug 2025confirmed

Confirmed across sources Institutional holdings and Short interest and volume

aTyr Pharma (ATYR): saw 47 13F filers open a new position in the quarter ended 30 Jun 2025, 12× the same quarter last year, while it had 28.2M shares sold short in the 15 Aug 2025 report, 81× the same report last year. Two unrelated kinds of activity within 77 days.

  • Short interest and volume: Short interest spike, became public on 25 Jul 2025
  • Short interest and volume: Short interest spike, became public on 12 Aug 2025
  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2025
  • Short interest and volume: Short interest spike, became public on 27 Aug 2025
  • Short interest and volume: Short interest spike, became public on 11 Sep 2025
  • Short interest and volume: Short interest spike, became public on 25 Sep 2025
  • Short interest and volume: Short interest spike, became public on 10 Oct 2025
2023-06-30: 102023-09-30: 52023-12-31: 62024-03-31: 142024-06-30: 42024-09-30: 112024-12-31: 272025-03-31: 242025-06-30: 47
The quarter ended 30 Jun 2025 against the 8 quarters before it. this quarterearliernormal: 10.5
See the evidence (7 changes)

Short interest and volume: Short interest spike became public on 25 Jul 2025

aTyr Pharma had 20.4M shares sold short in the 15 Jul 2025 report, 61× the same report last year.

This period
20.4M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
3.0M
How far from its usual level
+3.8
Same report last year
337K
History used
396 days
2024-07-15: 337K2024-07-31: 271K2024-08-15: 347K2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M
the 15 Jul 2025 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Aug 2025

aTyr Pharma had 25.6M shares sold short in the 31 Jul 2025 report, 95× the same report last year.

This period
25.6M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
3.1M
How far from its usual level
+4.7
Same report last year
271K
History used
412 days
2024-07-31: 271K2024-08-15: 347K2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M
the 31 Jul 2025 report24 earlier reportsnormal: 3.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Aug 2025

aTyr Pharma saw 47 13F filers open a new position in the quarter ended 30 Jun 2025, 12× the same quarter last year.

This period
47 (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
5
How far from its usual level
+4.9
Same quarter last year
4
History used
3,653 days
2023-06-30: 102023-09-30: 52023-12-31: 62024-03-31: 142024-06-30: 42024-09-30: 112024-12-31: 272025-03-31: 242025-06-30: 47
the quarter ended 30 Jun 20258 earlier quartersnormal: 10.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 27 Aug 2025

aTyr Pharma had 28.2M shares sold short in the 15 Aug 2025 report, 81× the same report last year.

This period
28.2M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
4.1M
Typical spread (median absolute deviation)
3.2M
How far from its usual level
+5.1
Same report last year
347K
History used
427 days
2024-08-15: 347K2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M
the 15 Aug 2025 report24 earlier reportsnormal: 4.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Sep 2025

aTyr Pharma had 29.4M shares sold short in the 29 Aug 2025 report, 67× the same report last year.

This period
29.4M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
3.6M
How far from its usual level
+4.6
Same report last year
441K
History used
441 days
2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M2025-08-29: 29.4M
the 29 Aug 2025 report24 earlier reportsnormal: 4.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Sep 2025

aTyr Pharma had 33.1M shares sold short in the 15 Sep 2025 report, 48× the same report last year.

This period
33.1M (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
6.1M
Typical spread (median absolute deviation)
4.6M
How far from its usual level
+4.0
Same report last year
686K
History used
458 days
2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M2025-08-29: 29.4M2025-09-15: 33.1M
the 15 Sep 2025 report24 earlier reportsnormal: 6.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Oct 2025

aTyr Pharma had 37.9M shares sold short in the 30 Sep 2025 report, 28× the same report last year.

This period
37.9M (the 30 Sep 2025 report)
Normal report (median of 24 earlier)
7.6M
Typical spread (median absolute deviation)
5.5M
How far from its usual level
+3.7
Same report last year
1.4M
History used
473 days
2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M2025-08-29: 29.4M2025-09-15: 33.1M2025-09-30: 37.9M
the 30 Sep 2025 report24 earlier reportsnormal: 7.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 31 Jul 2026Filings record

    A major agreement ended

  2. 8 Jun 2026Filings record

    Delisting notice or listing transfer

  3. 29 May 2026Insiders record

    SCHIMMEL PAUL (director) bought 100,000 shares of ATYR ($50,000) (dated 28 May 2026)

  4. 5 Dec 2025Filings record

    Delisting notice or listing transfer

  5. 10 Oct 2025Short interest and volume change

    had 37.9M shares sold short in the 30 Sep 2025 report, 28× the same report last year.

    Same report last year: 1.4M; its normal report is 7.6M.

    See the evidence
    This period
    37.9M (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    7.6M
    Typical spread (median absolute deviation)
    5.5M
    How far from its usual level
    +3.7
    Same report last year
    1.4M
    History used
    473 days
    2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M2025-08-29: 29.4M2025-09-15: 33.1M2025-09-30: 37.9M
    the 30 Sep 2025 report24 earlier reportsnormal: 7.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 10 Oct 2025Insiders record

    SCHIMMEL PAUL (director) bought 1,000,000 shares of ATYR ($912,720) (dated 9 Oct 2025)

  7. 25 Sep 2025Short interest and volume change

    had 33.1M shares sold short in the 15 Sep 2025 report, 48× the same report last year.

    Same report last year: 686K; its normal report is 6.1M.

    See the evidence
    This period
    33.1M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    6.1M
    Typical spread (median absolute deviation)
    4.6M
    How far from its usual level
    +4.0
    Same report last year
    686K
    History used
    458 days
    2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M2025-08-29: 29.4M2025-09-15: 33.1M
    the 15 Sep 2025 report24 earlier reportsnormal: 6.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 11 Sep 2025Short interest and volume change

    had 29.4M shares sold short in the 29 Aug 2025 report, 67× the same report last year.

    Same report last year: 441K; its normal report is 4.8M.

    See the evidence
    This period
    29.4M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    4.8M
    Typical spread (median absolute deviation)
    3.6M
    How far from its usual level
    +4.6
    Same report last year
    441K
    History used
    441 days
    2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M2025-08-29: 29.4M
    the 29 Aug 2025 report24 earlier reportsnormal: 4.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 27 Aug 2025Short interest and volume change

    had 28.2M shares sold short in the 15 Aug 2025 report, 81× the same report last year.

    Same report last year: 347K; its normal report is 4.1M.

    See the evidence
    This period
    28.2M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    4.1M
    Typical spread (median absolute deviation)
    3.2M
    How far from its usual level
    +5.1
    Same report last year
    347K
    History used
    427 days
    2024-08-15: 347K2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M
    the 15 Aug 2025 report24 earlier reportsnormal: 4.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 14 Aug 2025several at once

    saw 47 13F filers open a new position in the quarter ended 30 Jun 2025, 12× the same quarter last year, while it had 28.2M shares sold short in the 15 Aug 2025 report, 81× the same report last year. Two unrelated kinds of activity within 77 days.

    See the evidence (7 changes)

    Short interest and volume: Short interest spike became public on 25 Jul 2025

    aTyr Pharma had 20.4M shares sold short in the 15 Jul 2025 report, 61× the same report last year.

    This period
    20.4M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    3.0M
    How far from its usual level
    +3.8
    Same report last year
    337K
    History used
    396 days
    2024-07-15: 337K2024-07-31: 271K2024-08-15: 347K2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M
    the 15 Jul 2025 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Aug 2025

    aTyr Pharma had 25.6M shares sold short in the 31 Jul 2025 report, 95× the same report last year.

    This period
    25.6M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    3.1M
    How far from its usual level
    +4.7
    Same report last year
    271K
    History used
    412 days
    2024-07-31: 271K2024-08-15: 347K2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M
    the 31 Jul 2025 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2025

    aTyr Pharma saw 47 13F filers open a new position in the quarter ended 30 Jun 2025, 12× the same quarter last year.

    This period
    47 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    10.5
    Typical spread (median absolute deviation)
    5
    How far from its usual level
    +4.9
    Same quarter last year
    4
    History used
    3,653 days
    2023-06-30: 102023-09-30: 52023-12-31: 62024-03-31: 142024-06-30: 42024-09-30: 112024-12-31: 272025-03-31: 242025-06-30: 47
    the quarter ended 30 Jun 20258 earlier quartersnormal: 10.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 27 Aug 2025

    aTyr Pharma had 28.2M shares sold short in the 15 Aug 2025 report, 81× the same report last year.

    This period
    28.2M (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    4.1M
    Typical spread (median absolute deviation)
    3.2M
    How far from its usual level
    +5.1
    Same report last year
    347K
    History used
    427 days
    2024-08-15: 347K2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M
    the 15 Aug 2025 report24 earlier reportsnormal: 4.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Sep 2025

    aTyr Pharma had 29.4M shares sold short in the 29 Aug 2025 report, 67× the same report last year.

    This period
    29.4M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    4.8M
    Typical spread (median absolute deviation)
    3.6M
    How far from its usual level
    +4.6
    Same report last year
    441K
    History used
    441 days
    2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M2025-08-29: 29.4M
    the 29 Aug 2025 report24 earlier reportsnormal: 4.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Sep 2025

    aTyr Pharma had 33.1M shares sold short in the 15 Sep 2025 report, 48× the same report last year.

    This period
    33.1M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    6.1M
    Typical spread (median absolute deviation)
    4.6M
    How far from its usual level
    +4.0
    Same report last year
    686K
    History used
    458 days
    2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M2025-08-29: 29.4M2025-09-15: 33.1M
    the 15 Sep 2025 report24 earlier reportsnormal: 6.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Oct 2025

    aTyr Pharma had 37.9M shares sold short in the 30 Sep 2025 report, 28× the same report last year.

    This period
    37.9M (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    7.6M
    Typical spread (median absolute deviation)
    5.5M
    How far from its usual level
    +3.7
    Same report last year
    1.4M
    History used
    473 days
    2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M2025-08-15: 28.2M2025-08-29: 29.4M2025-09-15: 33.1M2025-09-30: 37.9M
    the 30 Sep 2025 report24 earlier reportsnormal: 7.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  11. 14 Aug 2025Institutional holdings change

    saw 47 13F filers open a new position in the quarter ended 30 Jun 2025, 12× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 10.5.

    See the evidence
    This period
    47 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    10.5
    Typical spread (median absolute deviation)
    5
    How far from its usual level
    +4.9
    Same quarter last year
    4
    History used
    3,653 days
    2023-06-30: 102023-09-30: 52023-12-31: 62024-03-31: 142024-06-30: 42024-09-30: 112024-12-31: 272025-03-31: 242025-06-30: 47
    the quarter ended 30 Jun 20258 earlier quartersnormal: 10.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  12. 12 Aug 2025Short interest and volume change

    had 25.6M shares sold short in the 31 Jul 2025 report, 95× the same report last year.

    Same report last year: 271K; its normal report is 3.7M.

    See the evidence
    This period
    25.6M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    3.1M
    How far from its usual level
    +4.7
    Same report last year
    271K
    History used
    412 days
    2024-07-31: 271K2024-08-15: 347K2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M2025-07-31: 25.6M
    the 31 Jul 2025 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 7 Aug 2025Filings record

    Asset write-down (impairment)

  14. 25 Jul 2025Short interest and volume change

    had 20.4M shares sold short in the 15 Jul 2025 report, 61× the same report last year.

    Same report last year: 337K; its normal report is 3.6M.

    See the evidence
    This period
    20.4M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    3.0M
    How far from its usual level
    +3.8
    Same report last year
    337K
    History used
    396 days
    2024-07-15: 337K2024-07-31: 271K2024-08-15: 347K2024-08-30: 441K2024-09-13: 686K2024-09-30: 1.4M2024-10-15: 1.1M2024-10-31: 1.7M2024-11-15: 2.1M2024-11-29: 2.2M2024-12-13: 2.9M2024-12-31: 3.6M2025-01-15: 3.5M2025-01-31: 3.8M2025-02-14: 4.4M2025-02-28: 5.3M2025-03-14: 6.9M2025-03-31: 8.3M2025-04-15: 10.0M2025-04-30: 11.7M2025-05-15: 12.7M2025-05-30: 13.8M2025-06-13: 13.6M2025-06-30: 18.5M2025-07-15: 20.4M
    the 15 Jul 2025 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 6 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 6 May 2025Filings record

    Director or officer change

  17. 18 Mar 2025Insiders record

    Gross Jane A (director) bought 3,750 shares of ATYR ($15,000) (dated 17 Mar 2025)

  18. 14 Feb 2025Institutional holdings change

    saw 27 13F filers open a new position in the quarter ended 31 Dec 2024, 4.5× the same quarter last year.

    Same quarter last year: 6; its normal quarter is 8.5.

    See the evidence
    This period
    27 (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    8.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +5.0
    Same quarter last year
    6
    History used
    3,472 days
    2022-12-31: 82023-03-31: 92023-06-30: 102023-09-30: 52023-12-31: 62024-03-31: 142024-06-30: 42024-09-30: 112024-12-31: 27
    the quarter ended 31 Dec 20248 earlier quartersnormal: 8.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  19. 12 Dec 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 12 Dec 2024Filings record

    Director or officer change

  21. 25 Jul 2024Insiders record

    SCHIMMEL PAUL (director) bought 100,000 shares of ATYR ($184,469) (dated 24 Jul 2024)

  22. 7 Jun 2024Insiders record

    DENYES NANCY (General Counsel) bought 5,000 shares of ATYR ($9,300) (dated 6 Jun 2024)

  23. 4 Jun 2024Insiders change

    had 3 insiders buy $133K of its shares on the open market within 30 days (3 filings).

    Who bought: Shukla Sanjay, Coughlin Timothy, Broadfoot Jill Marie.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $133K
    Window
    5 May 2024 to 4 Jun 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  24. 4 Jun 2024Insiders record

    Broadfoot Jill Marie (Chief Financial Officer) bought 5,000 shares of LIFE ($8,950) (dated 3 Jun 2024)

  25. 4 Jun 2024Insiders record

    COUGHLIN TIMOTHY (director) bought 50,000 shares of LIFE ($87,500) (dated 3 Jun 2024)

  26. 4 Jun 2024Insiders record

    Shukla Sanjay (President and CEO) bought 20,000 shares of LIFE ($36,200) (dated 3 Jun 2024)

  27. 29 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 29 May 2024Filings record

    Director or officer change

  29. 13 Dec 2023Insiders record

    Shukla Sanjay (President and CEO) bought 15,000 shares of LIFE ($17,670) (dated 12 Dec 2023)

  30. 14 Nov 2023Insiders record

    Shukla Sanjay (President and CEO) bought 15,000 shares of LIFE ($16,693) (dated 13 Nov 2023)

  31. 2 Aug 2023Insiders record

    Shukla Sanjay (President and CEO) bought 15,000 shares of LIFE ($30,150) (dated 1 Aug 2023)

  32. 19 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 19 May 2023Filings record

    Director or officer change

  34. 12 May 2023Insiders record

    SCHIMMEL PAUL (director) bought 200,000 shares of LIFE ($450,000) (dated 11 May 2023)

  35. 22 Nov 2022Insiders record

    Shukla Sanjay (President and CEO) bought 10,000 shares of LIFE ($21,400) (dated 21 Nov 2022)

  36. 7 Jul 2022Insiders record

    Shukla Sanjay (President and CEO) bought 15,000 shares of LIFE ($43,200) (dated 6 Jul 2022)

  37. 28 Apr 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 28 Apr 2022Filings record

    Director or officer change

  39. 22 Apr 2022Filings record

    A major agreement ended

  40. 19 Jan 2022Insiders record

    Broadfoot Jill Marie (Chief Financial Officer) bought 1,923 shares of LIFE ($12,980) (dated 18 Jan 2022)

Showing the newest 40 of 105 entries; narrow the window or the kind of data to see older ones.

Not listed: 154 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001339970
Ticker
ATYR
Domain
atyrpharma.com
Hq location
CA|SAN DIEGO|92121 (1 unverified)
Name
aTyr Pharma, Inc.
Wikidata
Q30286352
Wikipedia
ATyr Pharma
  • SEC Form 13F institutional holdings414 data points30 Jun 2015 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)170 records29 Jan 2016 to 13 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)681 data points31 Dec 2012 to 2 Nov 2026
  • SEC Form 4 insider transactions72 records, 224 data points6 Apr 2016 to 28 May 2026
  • FINRA short interest (twice monthly)174 data points14 Jun 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1238 data points5 Jun 2024 to 20 Nov 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026